Genitourinary syndrome of menopause is among the most consequential diagnoses in midlife women’s health and among the least made. It is worth understanding as a single condition, because that is how it behaves and how it should be treated.
This piece covers the mechanism, why it is missed, and what a practice needs in order to manage it properly.
In Summary:
| GSM covers vaginal, sexual and urinary symptoms arising from estrogen loss, and it is one condition rather than several. |
| It is progressive, which makes it clinically distinct from most menopausal symptoms. |
| Under-treatment is driven by three things: patients not raising it, clinicians not asking, and confusion between local and systemic estrogen. |
| Recurrent urinary tract infections after menopause belong in this conversation. |
What the term covers
GSM describes the vaginal, sexual and urinary symptoms that follow the loss of estrogen at menopause. That includes vaginal dryness, pain with sex, itching and burning, urinary urgency and frequency, and recurrent urinary tract infections.
The terminology matters clinically. Earlier language, vaginal atrophy or atrophic vaginitis, described the vaginal findings and left the urinary symptoms outside the diagnosis. Patients were consequently treated for one part of a single condition, often by different clinicians who did not connect the two.
The mechanism, in one paragraph
Estrogen receptors are present throughout the vulva, vagina, urethra and bladder. As estrogen falls, the epithelium thins, elasticity reduces, blood flow decreases, secretions diminish and vaginal pH rises, which alters the vaginal microbiome. Every symptom in the list follows from that. This is why a condition that presents in three apparently separate domains responds to a single treatment.
Why it is progressive, and why that changes management
This is the point that most distinguishes GSM from the rest of the menopausal symptom picture.
Vasomotor symptoms have a natural history. Median total duration of hot flashes and night sweats in the Study of Women’s Health Across the Nation was around seven and a half years, so a patient who chooses to wait is waiting for something that will eventually ease.
GSM has no such trajectory. The tissue change continues for as long as estrogen remains low, so symptoms typically worsen without treatment. Advising a patient to see how things go is therefore a different clinical act here than it is for hot flashes, and it should be made deliberately rather than by default.
The three reasons it goes untreated
First, patients do not raise it. Stigma, an assumption that this is simply aging, and prior dismissal all contribute. Surveys consistently find most affected women never mention it.
Second, clinicians do not ask. The subject is absent from most intake forms and most review appointments, and many clinicians were never taught how to open it.
Third, and most correctable, local and systemic estrogen are confused with one another. When a patient believes vaginal estrogen carries the risk profile of systemic hormone therapy, or when a clinician does, a well-supported treatment goes unused. Outdated labeling sustained that confusion for years.
What treatment requires
Non-hormonal measures have a place. Vaginal moisturizers used regularly improve tissue condition, and lubricants used at the time of sex reduce friction. They perform different functions, and patients should be told which is which.
Local vaginal estrogen has the strongest evidence base and is the treatment most often omitted. It is available as a cream, tablet or ring, acts locally with minimal systemic absorption, and does not require a progestogen for endometrial protection at standard doses. Improvement is gradual over weeks, and benefit reverses on discontinuation, because the underlying tissue change resumes. Patients should know that at the outset so they do not read it as failure.
The evidence on breast cancer risk with local vaginal estrogen has been reassuring, and it derives largely from observational data rather than long-term randomized trials. That is worth stating accurately rather than overstating in either direction. Patients with a personal history of breast cancer are managed with their oncology team.
The urinary tract infection connection
A patient who has had repeated courses of antibiotics since menopause is frequently a patient with untreated GSM. Local vaginal estrogen has evidence for reducing recurrent urinary tract infections, which makes it a preventive intervention as well as a symptomatic one.
An active infection still requires its own testing and treatment. The point is that repeat prescribing without addressing the underlying tissue change treats the episode and not the cause.
Escalation rules your protocol needs
Any bleeding after twelve period-free months requires prompt assessment and must not be attributed to thin tissue without investigation, even though atrophy is the most common cause of postmenopausal bleeding. ACOG guidance updated in April 2026 advises ultrasound and endometrial sampling together as the initial assessment.
Persistent vulvar itching, a white or thickened patch, a lump, an ulcer, or a non-healing sore all require examination. Lichen sclerosus becomes more common after menopause and needs different treatment and ongoing monitoring.
Genitourinary syndrome of menopause. It replaced earlier terms such as vulvovaginal atrophy, which excluded the urinary symptoms from the diagnosis.
Clinically, from symptoms and examination findings. No test is required to make the diagnosis, though examination is important to exclude other vulvar conditions.
No. Unlike vasomotor symptoms, GSM progresses while estrogen remains low, which is why deferring treatment has a different cost here.
Not at standard local doses for endometrial protection. Systemic estrogen does require it in patients with a uterus.
Improvement is gradual over weeks rather than immediate, and symptoms return if treatment stops because the underlying tissue change resumes.
Yes. Local vaginal estrogen has evidence for reducing recurrence. Active infections still require their own testing and treatment.
Any postmenopausal bleeding requires assessment in its own right. Persistent itching, thickened or white patches, lumps, ulcers or non-healing sores require examination.
